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Hypercalcemia (HC) has been variably reported in kidney transplanted (KTx) recipients (5–15%). Calcium levels peak around
the 3rd month after KTx and thereafter slightly reduce and stabilize. Though many factors have been claimed to induce HC after
KTx, the persistence of posttransplant hyperparathyroidism (PT-HPT) of moderate-severe degree is universally considered the
first causal factor. Though not proven, there are experimental and clinical suggestions that HC can adversely aﬀect either the graft
(nephrocalcinosis) and other organs or systems (vascular calcifications, erythrocytosis, pancreatitis, etc.). However, there is no
conclusive evidence that correction of serum calcium levels might avoid the occurrence of these claimed clinical eﬀects of HC. The
best way to reduce the occurrence of HC after KTx is to treat as best we can the secondary hyperparathyroidism (SHP) during the
uraemic stages. The indication to Parathyroidectomy (PTX), either before or after KTx, in order to prevent or to treat, respectively,
HC after KTx, is still a matter of debate which has been revived by the availability of the calcimimetic cinacalcet for the treatment
of PT-HPT. However, we still need to better clarify many points as regards the potential adverse eﬀects related to either PTX or
cinacalcet use in this clinical set, and we are waiting for the results of future randomized controlled trials to achieve some more
definite conclusions on this topic.
1. Introduction
Though kidney transplant (KTx) might induce a regression
of most metabolic derangements characterizing end-stage
renal disease (ESRD), electrolyte disturbances are not unco-
mmonly encountered in patients with an even well-functio-
ning renal graft.
Limiting ourselves to mentioning only the most fre-
quent electrolyte disturbances, we would like to list:
metabolic acidosis, hypo- and hyperkaliemia, hypomagne-
siemia, hypophosphatemia, and hypercalcemia [1–6].
Over the last decade, hypercalcemia (HC) has received
much attention from the renal transplant community since
it has been claimed to have a negative impact on both the
graft and patient outcomes.
In the following paragraphs, we will deal with the main
pathogenic aspects, the most relevant clinical consequences,
and the possible therapeutic approach of the HC in KTx
patients.
2. Prevalence of HC after KTx
HC has been reported to occur with an extremely variable
incidence after KTx (from <5% up to >50%) [3, 6–12].
Table 1 shows the main characteristics of some of the
most relevant studies, reporting on HC prevalence after KTx.
The high variability of prevalence of HC might be explained
at least in part by a number of factors.
First, it is worth noting that the older the study was the
higher the prevalence of HC was evident, probably due to a
less eﬃcient control of SHP in earlier studies.
Second, it is also worth stressing that most studies had
a cross-sectional and retrospective design and included a
relatively low number of patients or only part of the global
cohort of transplanted patients. This might have introduced
a selection bias, where only patients with previously recog-
nized severe hyperparathyroidism were included.
Third, the time elapsed from the time of transplantation
to the time when serum calcium levels were evaluated was
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Table 1: Prevalence of Hypercalcemia (HC) after Kidney Transplantation (KTx) in diﬀerent studies.
Reference
Study
protocol
N.
of
pts
Definition of HC
Time of observation
(months from KTx)
% of HC
Vit D
suppl
David et al.
[6]
RS 64 tot-sCa >2.75 mmol/L nd 34% nr
Cundy et al.
[7]
POS 100 tot-sCa > 2.65 mmol/L
Multiple assessments from
the 2nd to the 24th month
12th → 20%
24th → 12% nr
Reinhardt et al.
[3]
POS 129
corr. tot-sCa >
2.95 mmol/L
Multiple assessments from
the 2nd to the 24th month
3rd → 52%
12th → 23%
24th → 10%
No
Leca et al.
[8]
nr-PIS 213 tot-sCa > 2.625 mmol/L 6th month 9.9% No
Egbuna et al.
[9]
RS 303
corr. tot-sCa >
2.55 mmol/L
Multiple assessments from
the 2nd to the 12th month
3rd → 8%
12th → 9% nr
Ramezani et al.
[10]
RS 398 tot-sCa > 2.625 mmol/L
Assessment over the first12
months
4.5% nr
Evenepoel et al.
[11]
POS 201
corr. tot-sCa or
tot-sCa
> 2.575 mmol/L
Multiple assessments over
the first 3 months
corr. tot-sCa → up to 14%
tot-sCa → up to 27% No
Evenepoel et al.
[12]
POS 268
i-sCa > 1.29 mol/L or
corr. tot-sCa
> 2.575 mmol/L
Multiple assessments over
the first 12 months
i-sCa → up to 58.6%
corr. tot-sCa → up to 13.1% nr
POR = prospective observational study, RS: retrospective study, nr-PIS: not randomized prospective intervention study, tot-sCa: total serum Calcium, corr-
tot-sCa: total serum calcium corrected for albumin, i-sCa: ionized serum calcium; nd: not defined, nr: not reported.
consistently variable in the diﬀerent studies. In fact, an
increase in HC prevalence would be expected during the
first year after KTx, with a reduction thereafter. However,
the changes in the prevalence of HC over time was also
consistently diﬀerent among the various studies. In fact,
some AA reported that calcium levels had a trend toward
an early reduction (first 3 months) and then increased up
to the sixth month, stabilizing thereafter over all the first
year [11, 13], while others [9] found an almost constant
prevalence of HC over all the first year after KTx.
A fourth possible confounding factor might be a possible
diﬀerent use of vitamin D and/or calcium supplements in
the KTx patients. In fact, most of the quoted studies do not
report on this aspect.
Another possible confounder in the evaluation of the real
prevalence of HC in transplanted patients is the diﬀerent
methodology used for calcium assessment. In fact, it has been
reported that elevated Ca levels might be often overlooked if
evaluated as total serum Ca rather than ionized serum Ca,
since the former underestimates HC in KTx patients [12].
This eﬀect can be only in part explained by the reduction
of serum albumin levels, which often characterize the early
period after KTx, since the total serum calcium corrected by
albumin does not predict ionized calcium levels substantially
better than the uncorrected ones [12].
Finally, these diﬀerent results might also be explained by
diﬀerences among the various transplant centres in the wait-
listing policy for the patients with severe SHP.
Summarizing, though HC after KTx has been reported
to occur with an extremely high variability, when calcium
levels are evaluated by the appropriate methodology (ionized
calcium), its prevalence is relatively high, particularly during
the first year.
3. Pathogenic Mechanisms of HC in
KTx Patients
The first-well recognized factor in causing the occurrence of
HC after KTx is the persistence of SHP after transplantation
[11, 13].
PT-HPT after KTx is much more likely to occur when
a severe form of SHP was present during the uraemic state
preceding KTx.
It is also well acknowledged that the most severe degree
of SHP is almost invariably associated with the nodular form
of parathyroid gland hyperplasia which is much less prone to
undergo spontaneous regression even after the uraemic state
has been corrected [11, 14]. This also explains why, when
the uraemic milieu has been corrected, the phosphate levels
have been reduced, and the bone cell sensitivity to both PTH
and vitamin D has been recovered by a functioning renal
graft, the exceedingly high PTH levels are more eﬀective in
inducing HC due to enhanced bone response to its calcemic
action [15].
However, the increased PTH-mediated bone resorption
does not seem to be the only mechanism responsible for the
HC in renal transplanted patients. One of the few studies
which explored the skeletal status in KTx by bone biopsy
found that HC was indiﬀerently associated to either the
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Figure 1: The main supposed mechanisms responsible for the occurrence of hypercalcemia after kidney transplant. (Pi: inorganic
phosphorus; CNI: calcineurin inhibitors; RAPA: rapamycin; FGF23: fibroblast growth factor 23).
increased bone turnover disease or to the adynamic bone
disease [16].
Another potential factor causing HC after KTx is the
recovered circulating levels of calcitriol, secondary to its
increased renal tubular synthesis, further stimulated by the
inappropriately high PTH and low phosphorus levels. The
recovered calcitriol levels might concur in inducing HC by
both its intestinal and bone eﬀects [17].
This potential hypercalcemic condition might be in part
counteracted by two opposing factors: the persistence of
elevated FGF-23 levels, which is a strong inhibitor of 1-
α-OHase activity, and the very frequent occurrence of the
deficiency/insuﬃciency of the calcitriol precursor, calcifediol
in KTx patients [18, 19]. This point might have some
therapeutic consequences, as will be discussed more in depth
later on. In fact, with the progressive reduction of FGF23,
which is often observed after a few months from KTx, and
particularly when patients are supplemented with vitamin D,
overt HC might develop.
Another factor which has been cited as a potential cause
of HC after KTx is the supposed reabsorption of vascular
calcifications (VC) [20]. However, there are no data in the lit-
erature supporting the above hypothesis, and on the contrary
some AA have reported a trend toward an increase of VC after
KTx [21, 22]. Furthermore, some preliminary data of ours
[23] seem to suggest that the higher the serum calcium levels,
the higher the progression of VC after KTx. From all these
data, it seems quite unlikely that VC reabsorption might play
any major role among the causes of HC of KTx patients.
Whether diﬀerent immune-suppressive drugs might be
in some way related to HC is not completely clear. Steroids
have been recognized to carry with them a number of eﬀects
potentially aﬀecting calcium metabolism (antivitamin D
eﬀect, calciuretic activity, induction of osteoblast apoptosis,
etc.). However, most of these eﬀects are expected to induce
more hypocalcemia rather than hypercalcemia [24].
There is some evidence that calcineurin inhibitors
(CNIs), in particular cyclosporine, might increase bone
resorption and thus potentially promote the development
of HC [25]. However, there is no clear data supporting this
putative hypercalcemic eﬀect of CNIs.
A recent paper reported that KTx patients on rapamycin
therapy would be more prone to develop persistent SHP,
frequently associated with HC [26].
Finally, the possibility that some polymorphic variations
in genes coding for some calcium controlling factors might
increase the propensity to develop HC after KTx cannot
be excluded. In fact, some years ago we found that the BB
polymorphic variant of Vitamin D receptor (VDR) gene was
associated with lower prevalence of HC PT-HPT [13]. Our
results were substantially confirmed by further data [27].
More recently, a genome-wide association study (GWAS) has
clearly demonstrated that a single nucleotide polymorphism
in the gene coding for the calcium sensing receptor (CaSR) is
strongly associated with the levels of serum calcium in the
general population [28]. Whether this genetic background
might contribute also to the occurrence of HC after KTx
might be also worth studying.
Taken together all these data strongly suggest that the
occurrence of HC after KTx is mostly sustained by the
persistence of a severe form of PT-HPT which is mainly
secondary to the previous state of mineral metabolism
4 International Journal of Nephrology
derangement developed throughout the often long story of
chronic kidney disease.
Figure 1 summarizes the main hypothesized pathogenic
mechanisms through which HC might develop after KTx.
4. Clinical Consequences of HC in KTx
There is some evidence that HC may have a negative clinical
impact on either the graft and/or the patient outcome.
Though it is not always easy to dissect the two clinical fields
from each other, we will deal with each one separately so as
to treat more clearly the topic.
4.1. Clinical Impact of HC on the Graft Outcome. A number
of experimental studies have clearly demonstrated that HC
can induce renal damage by diﬀerent mechanisms. In animal
models, three diﬀerent types of Calcium-mediated kidney
damage have been described. The first type is represented
by macroscopic nephrocalcinosis, which is characterized by
coarse deposits of calcium salts both in renal papillae and
the urinary tract which can be detected also by ultra-sound
and/or radiological examination. The second one is defined
microscopic nephrocalcinosis, characterized by smaller cal-
cium salt depositions at the tubular cell and/or the interstitial
space level and can be detected only by microscopic exami-
nation. The last type of Calcium-mediated kidney damage is
recognized as chemical nephrocalcinosis. This type of kidney
damage can be defined as unspecific morphologic and/or
functional cell changes which occur in the presence of HC
and can regress or reduce after calcium level correction. The
pathogenesis of this last type of kidney damage is mostly
speculative and has been ascribed to some hemodynamic
and biochemical eﬀects of HC (vasoconstriction; increased
natriuresis and diuresis; activation of a huge number of
enzymes, cytokines, growth factors; etc.), even in the absence
of any observable calcium salt deposition [29, 30].
The data present in the literature establishing a clear
relationship between the presence of high calcium levels and
kidney damage in humans and particularly in KTx patients
are scanty and not fully conclusive.
Some years ago, Nankivell et al. [31] pointed out that
microcalcifications were a common finding in protocol
biopsies performed in transplanted kidneys, since they were
observed in 43% and 79% of biopsies at 1 year and 10
years after KTx, respectively. Later studies demonstrated that
the presence of HC is associated with a higher prevalence
of calcium salt deposits within the transplanted kidney
and that this nephrocalcinosis can adversely aﬀect the graft
survival [9, 32–35]. At variance with these results, other AA
[36], though confirming that calcium deposits are frequently
found (44%) in transplanted kidney biopsies, were not able
to find any relationship between nephrocalcinosis and serum
calcium levels. On the other hand, in the experience of the
above AA it was the presence of low citrate and high oxalate
urinary excretion which were more associated with calcium
deposition within renal graft.
Independently of the presence or not of clear calcium
deposits, it is worth remembering that HC can induce an
indirect kidney damage, secondary to its well-recognized
sodiuretic and aquaretic eﬀects which, in addition to its
vasoconstrictor action, can consistently reduce renal perfu-
sion, inducing a fall in glomerular filtration rate, which can
progress in the long term from an initial functional form to
a stabilized organic kidney injury condition.
Summarizing, though we have no conclusive evidence
that HC can be responsible for the nephrocalcinosis, which
is frequently observed in kidney graft biopsies, there are
plausible reasons for thinking that persistently high serum
calcium levels might adversely aﬀect kidney graft outcome.
4.2. Clinical Impact of HC on the Patient Outcome. A number
of potential negative eﬀects of HC on diﬀerent tissues,
organs, and systems have been extensively reported in the
literature. In the following paragraphs, we will just limit
ourselves to briefly mention the most relevant ones which
can more frequently occur in KTx patients.
4.2.1. Cardiovascular Eﬀects of HC. It has been well acknowl-
edged for some time that acute changes in extracellular
calcium concentration might induce consensual changes
of intracellular calcium levels which are the ultimate con-
troller of cardiomyocyte and vascular smooth muscle cell
contraction and relaxation [37–39]. On the other hand,
there is not much evidence that chronic changes of serum
calcium levels, in particular chronic HC, might cause any
sustained cardiovascular eﬀect, either in healthy people or in
pathological conditions, such as in KTx patients.
However, there are some plausible reasons for believing
that sustained high calcium levels might have some potential
negative eﬀect at least on the vascular calcification (VC)
process. As previously mentioned, VCs not infrequently
tend to progress after KTx, even though at a lower rate as
compared with dialysis patients [21, 22, 40, 41]. Some of our
preliminary results, produced as yet only in abstract form
[23], suggested that aortic calcifications, evaluated according
to Kauppila et al. [42], increased in 30% of patients over
the first year after KTx. Furthermore, patients heading for
a progression of their VC process had consistently higher
serum Calcium levels as compared with patients who did not
have any VC worsening.
However, these data alone cannot be considered to be
definite proof of a casual role of HC in inducing negative
cardiovascular eﬀects. Randomized controlled studies are
needed for reaching a conclusive answer to this important
question.
4.2.2. Hematological Eﬀects. After KTx; increases in red
blood cell number and in hemoglobin levels are not infre-
quently observed [43]. Though the prominent causal factor
of the erythrocytosis in KTx patients can be recognized
in the recovered synthesis of erythropoietin (EPO) by
the functioning kidney graft, in the presence of a well-
responding bone marrow, after the correction of the uraemic
state, other potential players might be also involved in this
process.
Among them, an increased local and/or systemic activity
of renin-angiotensin-system (RAS) has been advocated as a
potential pathogenic factor, since RAS has been shown to
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increase EPO synthesis, and furthermore the use of either
ace-inhibitors or angiotensin-receptor blockers has been
demonstrated to be eﬀective in controlling posttransplant
erythrocytosis [44, 45].
Recently, it has been suggested that calcium may con-
tribute to the RAS-mediated EPO stimulation [46]. Fur-
thermore, recently some AA reported that posttransplant
erythrocytosis is 2-3 times more frequent in KTx patients
who have higher serum calcium levels as compared with
normocalcemic patients [47, 48]. However, there are as yet
no data demonstrating that the correction of HC might
translate into a correction of posttransplant erythrocytosis.
4.2.3. Gastrointestinal Eﬀects. Severe HC, particularly encou-
ntered in the most advanced stages of neoplasias, can be
complicated by a relevant pancreatic damage [49]. If this
is also true for the degree of HC usually observed in KTx
patients is not clear.
Two decades ago, Frick et al. [50], studying 224 con-
secutive KTx patients, reported 8 patients who experienced
an acute pancreatitis episode and 20 patients who had an
asymptomatic increase of serum pancreatic enzymes. The
AA did not observe any association between the pancreatitis
episodes and the well-known specific risk factors, such as
immune suppressive therapy doses, viral infections, alcohol
consumption, or biliary tract lithiasis. The only factor which
was significantly associated with the pancreatitis episodes
was the presence of HC. However, no further paper, as far
as we know, has been published in the following decades
proving or disproving these findings.
In conclusion, it has been suggested that HC occurring
after a KTx can negatively impact both graft and patient clin-
ical outcomes. However, there is no evidence which clearly
demonstrates the mechanisms by which these negative eﬀects
might act, nor can we exclude that the high PTH levels, which
are almost invariably associated with HC, more than the
elevated calcium level per se, might be the possible primary
adverse factor.
Furthermore, it is still to be demonstrated which is the
threshold calcium concentration, if any, over which these
negative eﬀects can happen.
5. Therapeutic Intervention
The presence of persistently elevated serum calcium concen-
trations, associated with elevated PTH levels, has for some
time been considered a possible indication to parathyroidec-
tomy (PTX) in KTx patients.
However, it is worth underlining that there is no guide-
line for establishing which are the PTH and the serum
calcium levels over which the indication to PTX should be
given in the KTx clinical set. Therefore, the indication for the
PTX intervention is quite variable from one transplant centre
to another. Furthermore, there is no general agreement on
which type of PTX should be preferred: total, subtotal with
or without the auto-transplantation of a parathyroid gland.
It has long been considered that PTX might negatively
aﬀect the graft outcome, possibly due to either the haemo-
dynamic and/or immune-mediated changes triggered by the
acute changes in PTH and/or electrolyte concentrations after
the parathyroid gland removal [51, 52]. On the other hand,
recent data lessened this conviction, showing that no diﬀer-
ence in the long-term graft outcome was evident between
KTx patients who were submitted to PTX as compared with
a comparable group of patients who were not [53].
However, the need to face a PTX intervention is still a
matter of concern for many nephrologists in the early phase
after a KTx, given the burden of clinical problems which can
be present during this period. Furthermore, some of these
patients have already undergone such an intervention and for
this or any other reason they may not be prepared to undergo
a new intervention.
For this reason, many Transplant Centers warmly recom-
mend PTX in waiting-listed patients, before KTx when even
a moderate form of SHP is present.
Conflicting with this trend, other nephrologists advocate
some grounds for limiting the indication to PTX before KTx
to only the most severe forms of SHP. The main reason is
that there is some evidence which suggests that a regression
of parathyroid gland hyperplasia could be expected after a
well-functioning KTx. Some years ago, it was first reported
that the maximal PTH response to a hypocalcemic challenge,
which is considered a good marker of the functional
parathyroid gland mass, substantially reduced from the 1st to
the 6th month after renal transplantation [54]. More recently
it has been also reported that in the parathyroid glands
removed from KTx recipients, the cellular proliferative events
are reduced and apoptotic figures increased as compared to
the glands removed from uraemic patients on dialysis, even
though in both groups the parathyroid hyperplasia was in the
most advanced form characterized by nodular hyperplasia
[55]. These observed histological changes might suggest that
in the long run even the most severe form of SHP might be
expected to regress after KTx.
Reinforcing this view, recent papers observed a regression
of parathyroid gland volume, as assessed by US methodology,
in KTx patients treated with a calcimimetic drug [56, 57].
These observations introduce the second potential thera-
peutic approach to HC of KTx patients.
It is widely recognized that the introduction of cinacalcet,
as yet the only calcimimetic drug in clinical use, has consis-
tently increased the possibility for controlling, in particular,
the most severe forms of SHP in dialysis patients, reducing
the indications for PTX in this clinical set. This fact enhances
the complexity of the indication for PTX for the patients on a
transplant waiting-list who suﬀer from a severe form of SHP
which is well controlled by cinacalcet.
To further complicate this issue, it is worth remembering
that, at the present time, this drug has not been registered for
use also in transplanted patients.
On the other hand, a number of small studies have been
published in recent years on the use of cinacalcet in KTx
recipients which can give some indicative instruction on this
topic [8, 58–68].
The main results of these studies have been extensively
discussed in a recent review [69]. All these studies homoge-
neously demonstrated that cinacalcet is eﬀective in reducing
serum calcium concentration. Another constant finding of
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these studies was a consistent increase in serum phosphorus
levels. This last result can be considered a positive result,
since it is well known that KTx recipients are prone
to develop hypophosphatemia, which might contribute to
the skeletal problem frequently observed in transplanted
patients.
On the other hand, the behavior of PTH levels was
less homogeneous. In fact, though PTH levels significantly
reduced in most studies, the extent of these changes was quite
variable, since some authors described no significant change
at all [65] while others found up to a 40–50% reduction in
PTH levels [8, 60, 61].
It is also worth-underlining that only a part of these stud-
ies reported on the eﬀect of cinacalcet on urinary calcium
excretion. Furthermore, the results were very contradictory,
with unchanged, increased, or reduced calcium excretion
having been reported.
This variability might be at least in part dependent on
the time when the assessment was performed. In fact, in
the early treatment phase, when serum calcium levels (and
consequently the glomerular filtered load of calcium) are
still high, the reduction in renal tubular calcium absorption
induced by cinacalcet, due to both the reduced PTH levels
and to the cinacalcet direct calciuretic eﬀects, is expected
to induce high urinary calcium output. With ongoing
treatment, these eﬀects can be counteracted by the reduced
glomerular filtered calcium load, secondary to the reduction
of serum calcium levels which eventually bring its urinary
excretion back to the pretreatment levels.
On the other hand, we cannot rule out that some genetic
variability in the CaSR gene might play some role in the
possible variable calciuretic eﬀect of CaSR activation by
cinacalcet. In fact a recent paper demonstrated that some
polymorphic variants of the CaSR gene might play some role
in the diﬀerent urinary calcium excretion found in primary
hyperparathyroid patients with or without nephrolithiasis
[70].
Whatever the extent of the potential calciuretic eﬀect
of cinacalcet, this is a potentially negative eﬀect of the
drug, since, as previously mentioned, KTx patients are
already prone to develop nephrocalcinosis. So, any metabolic
change which might potentially increase this risk should be
considered with great caution. To reinforce this concern, a
case of nephrocalcinosis which occurred in a KTx patient
treated with cinacalcet has been recently reported [62].
The problem of nephrocalcinosis in KTx patients indi-
rectly introduces another linked therapeutic issue in this
clinical set. In fact, though KTx patients often present a
more or less severe vitamin D deficiency, there is much
controversy on whether this deficit should be replaced
even in the presence of elevated serum calcium levels. As
previously mentioned, it is also to be expected that also in
nonhypercalcemic KTx patients overt HC might ensue after
starting the replacement therapy with vitamin D metabolites.
However, some recent studies seem to minimize this concern,
since no relevant adverse event related to HC episodes have
been reported in KTx patients treated with cholecalciferol
[71, 72]. In any case, it seems to be advisable to carefully
check serum calcium levels when vitamin D therapy is
started. Whether the new less calcemic vitamin D analogues
would represent a clinical advantage also in this field deserves
specific prospective studies.
Although the potential eﬀects of cinacalcet treatment on
bone metabolism in KTx patients is an important issue, only
two papers have dealt with this problem. The first study
reported on a significant increase of bone mineral density
at the radial level in 9 patients treated with cinacalcet [64].
To the best of our knowledge, the second study was the only
one that prospectively examined bone histomorphometric
parameters in 10 transplant recipients before and after 18–
24-month treatment with cinacalcet [68]. The main results
were a decrease of bone formation rate in 7, an increase in
2, and no change in 1 patient. These conflicting results, far
from being conclusive, underline the need for gaining further
information on this critical issue.
Another point of potential concern is the possible
interference of cinacalcet with the immune-suppressive (IS)
drugs and its potential eﬀect on the graft function.
The first reports on the topic exploring the possible
interference between cinacalcet and the IS therapy demon-
strated no or only marginal eﬀects of cinacalcet on the blood
levels of the most frequently used immune-suppressive drugs
[73, 74]. However, following studies, though performed in
small groups of patients, provided results which suggest that
cinacalcet might reduce Tacrolimus AUC0−24 by approxi-
mately 14% and might also promote the accumulation of
a nephrotoxic metabolite of cyclosporine (AM19) [75, 76].
As far as the eﬀects of cinacalcet on renal function are
concerned, some of the quoted studies reported on the
change in serum creatinine levels and/or on the variably
evaluated glomerular filtration rate. The results were quite
variable with some studies showing a slight worsening [63,
73, 74], others a slight improvement [60, 64, 67], and the
other studies [58, 59, 65] no change of renal function at all.
It is worth stressing that the results of all the quoted
studies are flawed in many critical aspects, since most of
them were performed in relatively small groups of patients,
had a retrospective design, and a lack of a control group.
Furthermore, the criteria for choosing the treated patients
were not homogeneous, and many treated patients had
normal or slightly increased Ca levels before treatment, with
PTH levels only moderately increased. In fact, in our opinion
it is questionable to treat KTx patients with normocalcemic
PT-HPT with cinacalcet.
6. Conclusions and Opinions
HC after KTx is mainly the terminal event of an evolved
and uncontrolled SHP which maybe began long before
transplantation.
Even though not completely clear, it is plausible that HC
might negatively impact both graft and patient outcome.
The best way for avoiding HC after KTx is to optimally
treat SHP before KTx. However, two main questions still
remain unsolved.
The first question concerns the criteria for choosing
the patient on the transplant waiting-list who should be
referred to PTX or maintained on medical therapy. Given
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the complete lack of evidence on this issue, in our opinion
an absolute indication to PTX for a patient on the KTx
waiting list can be the presence of a severe SHP, defined by
contemporary high PTH levels (intact PTH > 800 pg/mL)
and HC (tot s-Ca > 10.4 mg/dl), which cannot be controlled
by the available medical therapy. A strong, though not
absolute, further indication to the surgical intervention
before renal transplantation might be also the presence of a
SHP controlled only by maximal doses of medical therapy.
In all the other cases, we do not believe that there is any
compelling indication to PTX.
A second critical point is the management of PT-HPT
associated with HC. PTX has long been considered the only
treatment of this clinical condition. However, independently
of its possible negative impact on graft function, which
moreover still remains unproven, PTX entails a number of
problems such as the type and the timing of the intervention
to be performed, the need for a continuous treatment for the
correction of the residual hypoparathyroidism after a suc-
cessful intervention, the problems related to some comorbid
clinical conditions which make the surgical intervention a
risk procedure and more. For all these reasons, the recent
availability of a medical approach to hypercalcemic PT-HPT
based on the use of cinacalcet challenged the concept of
considering PTX the best choice for this clinical condition.
However, it should be also considered that many
unsolved issues bring into question the prolonged use of
cinacalcet. These areas of uncertainty should be clarified by
a randomized controlled trial before a widespread use of the
drug can be suggested in KTx patients.
In this critical scenario, it is our opinion that cinacalcet
should be reserved to some specific cases such as the KTx
patients with PT-HPT associated with overt HC (> 12 mg/dl)
and have been already submitted to a previous PTX and/or
have clinical conditions which make the intervention a risk
procedure and/or refuse the intervention for any reason.
At the present time, the clinical evaluation of each single
patient still remains the best guide-line for choosing the best
treatment of HC in KTx patients.
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